This clinical trial, sponsored by the Chinese PLA General Hospital, aims to evaluate the efficacy and safety of chidamide as a bridging therapy in CAR-T treated patients with recurrent or refractory B-cell NHL. The study targets a significant unmet need in the oncology market, particularly for patients exhibiting low NOXA expression, which is associated with CAR-T resistance. The competitive landscape includes existing CAR-T therapies, but the integration of chidamide may provide a differentiated approach to enhance treatment outcomes. Given the increasing prevalence of NHL and the growing adoption of CAR-T therapies, successful results could position the sponsor favorably within the expanding biopharmaceutical market focused on hematologic malignancies.